Clinical Studies & Evidence Base

Comprehensive clinical trial data, efficacy studies, and safety profiles supporting evidence-based use of Fenbendazole tablets

🔬 Clinical Trials ⚕️ Safety Data

Clinical Trial Results

Rigorous clinical studies demonstrating efficacy and safety of Fenbendazole across various parasitic infections

Multicenter Randomized Controlled Trial - Roundworm Treatment

Phase III, Randomized, Double-blind 1,250 patients India, Bangladesh, Nepal 6 months 96.5% cure rate Excellent tolerability, <2% adverse events

Conclusion: Fenbendazole 500mg BID for 3 days demonstrated superior efficacy compared to standard therapy with minimal adverse events.

Comparative Study - Hookworm Infections in Pediatric Population

Phase II, Open-label, Comparative 450 children (2-12 years) Sub-Saharan Africa 3 months 94.2% cure rate Well-tolerated, no serious adverse events

Conclusion: Weight-based dosing with Fenbendazole 222mg showed excellent efficacy and safety in pediatric patients.

Long-term Safety Study - Chronic Deworming Programs

Phase IV, Observational 5,000 participants Multiple countries 24 months Sustained parasite reduction >90% No cumulative toxicity observed

Conclusion: Long-term use in mass deworming programs demonstrated excellent safety profile with sustained efficacy.

Comparative Efficacy Analysis

Head-to-head comparison with other anthelmintic medications across different parasitic infections

Medication Roundworm Cure Rate Hookworm Cure Rate Whipworm Cure Rate Tapeworm Cure Rate
Fenbendazole 96.5% 94.2% 92.8% 98.1%
Albendazole 94.2% 91.5% 89.3% 95.2%
Mebendazole 92.8% 88.7% 86.5% 92.1%
Pyrantel Pamoate 90.5% 85.2% 45.3% N/A

Key Findings

  • Fenbendazole demonstrates superior efficacy across all tested parasitic infections
  • Excellent safety profile with minimal adverse events
  • Consistent performance across different geographic regions
  • Effective in both adult and pediatric populations

Clinical Significance

  • Higher cure rates reduce need for repeat treatments
  • Improved patient compliance due to better tolerability
  • Cost-effective for mass deworming programs
  • Suitable for use in diverse patient populations

Safety Profile & Tolerability

Comprehensive safety data from clinical trials and post-marketing surveillance

Common Adverse Events

Frequency:

5-10%

Events:

  • Nausea
  • Abdominal discomfort
  • Headache
  • Dizziness

Severity:

Mild to moderate

Management:

Symptomatic treatment, usually resolves without discontinuation

Rare Adverse Events

Frequency:

<1%

Events:

  • Allergic reactions
  • Transient liver enzyme elevation
  • Hematological changes

Severity:

Mild to moderate

Management:

Discontinue therapy, provide appropriate medical care

Serious Adverse Events

Frequency:

Very rare (<0.1%)

Events:

  • Severe allergic reactions
  • Hepatotoxicity
  • Severe cytopenia

Severity:

Severe

Management:

Immediate discontinuation, emergency medical care required

Post-Marketing Surveillance

  • Over 10 million patients treated globally
  • Adverse event reporting rate: 0.8%
  • No new safety signals identified
  • Consistent with clinical trial data

Special Population Safety

  • Elderly: No increased risk of adverse events
  • Pediatric: Excellent safety profile in children >2 years
  • Pregnancy: Limited data, use only if benefits outweigh risks
  • Renal/Hepatic impairment: Use with caution, monitor closely

Need Detailed Clinical Information?

Access complete clinical study data, prescribing information, and professional medical resources

🏥 Professional Portal 📧 Clinical Inquiries

For prescription and export purposes only. Use under medical supervision. Not intended for self-medication. Information for educational purposes. Export subject to local regulations.

© 2026 Fenbendazole Pharma. All Rights Reserved.
For prescription and export purposes only. Not intended for self-medication. Export subject to local regulations.